AVTX-803 is under clinical development by Avalo Therapeutics and currently in Phase III for Inherited Metabolic Disorders. According to GlobalData, Phase III drugs for Inherited Metabolic Disorders have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how AVTX-803’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AVTX-803 overview

AVTX-803 is under development for the treatment of leukocyte adhesion deficiency type II (LADII) or congenital disorder of glycosylation type IIc in pediatrics. It is a L-fucose. The therapeutic candidate is a genetically-targeted, substrate replacement therapy administered orally.

Avalo Therapeutics overview

Avalo Therapeutics, formerly Cerecor is a biopharmaceutical company that develops and commercializes novel products in the fields of neurology and pediatrics. The company’s products include prescription medications, prescription devices and dietary supplements. Its pipeline products offer treatment in the areas of neurogenic orthostatic hypotension, parkinsons disease, seizures in epilepsy and deoxyguanosine kinase deficiency. Avalo Therapeutics’ prescription medications comprise aciphex sprinkle, cefaclor, millipred tablets and dose packs and millipred oral solution, among others. The company also offers dietary supplements such as chewable tablets and drops. Avalo Therapeutics is headquartered in Baltimore, Maryland, the US.

For a complete picture of AVTX-803’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.